Information Provided By: 
Fly News Breaks for May 6, 2016
PFE, WVE
May 6, 2016 | 08:27 EDT
Leerink analyst Michael Schmidt says Wave Life Sciences (WVE) announced a research, license and option agreement with Pfizer (PFE) which should will be viewed positively by investors. Schmidt notes that this is the first "platform deal" for Wave Life Sciences and should provide external validation of its technology. The analyst believes the deal terms are "favorable" for Wave Life Sciences, as it will have access to proprietary Pfizer technology. Schmidt reiterates an Outperform rating on Wave Life Sciences' shares.
News For WVE;PFE From the Last 2 Days
WVE
Apr 22, 2024 | 13:44 EDT
PFE
Apr 22, 2024 | 08:13 EDT
Pfizer announced that the European Commission, or EC, has granted marketing authorization for Emblaveo for the treatment of adult patients with complicated intra-abdominal infections, or cIAI, hospital-acquired pneumonia, or HAP, including ventilator-associated pneumonia, or VAP, and complicated urinary tract infections, or cUTI, including pyelonephritis. It is also indicated for the treatment of infections due to aerobic Gram-negative organisms in adult patients with limited treatment options.
